PDCD1 and esophageal squamous cell carcinoma: Importantly, PD‐1 inhibitor combined with anti‐angiogenesis therapy or chemotherapy also showed high antitumor activity in previously immunotherapy‐treated advanced ESCC patients, indicating strong potential for future treatment strategies, providing a promising second‐line treatment option as current standards face challenges.